Ironwood Pharmaceuticals Inc. (IRWD)

12.91
NASDAQ : Health Technology
Prev Close 13.11
Day Low/High 12.68 / 13.33
52 Wk Low/High 9.07 / 21.20
Avg Volume 1.49M
Exchange NASDAQ
Shares Outstanding 140.08M
Market Cap 2.02B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Ironwood Pharmaceuticals Announces Filing By Astellas Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals Announces Filing By Astellas Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that a new drug application (NDA) seeking approval of linaclotide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) in Japan...

Ironwood Pharmaceuticals (IRWD) Stock Gaining on Q4 Results

Ironwood Pharmaceuticals (IRWD) Stock Gaining on Q4 Results

Ironwood Pharmaceuticals (IRWD) stock is higher late Friday afternoon following the release of its 2015 fourth quarter results after yesterday’s closing bell.

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2015 Investor Update

Ironwood Pharmaceuticals Provides Fourth Quarter And Full Year 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2015 results and recent business activities.

Ironwood Pharmaceuticals Progresses Vascular And Fibrotic Disease Platform With Positive Top-Line Phase Ia Data On Soluble Guanylate Cyclase Stimulator IW-1701

Ironwood Pharmaceuticals Progresses Vascular And Fibrotic Disease Platform With Positive Top-Line Phase Ia Data On Soluble Guanylate Cyclase Stimulator IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced positive top-line data from a Phase Ia study of IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator from Ironwood's vascular and...

Ironwood Pharmaceuticals To Present At 2016 RBC Capital Markets Global Healthcare Conference

Ironwood Pharmaceuticals To Present At 2016 RBC Capital Markets Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2016 RBC Capital Markets Global Healthcare Conference on Wednesday, February 24, 2016 at 4:05 p.

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2015 investor update conference call and webcast at 4:30 p.

(Graphic: Business Wire)

(Graphic: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today detailed its strategy to build a top-performing commercial biotechnology company generating rapid, sustainable, high-margin growth.

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Ironwood Pharmaceuticals (IRWD) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 34 th Annual J.

Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders

Insider Trading Alert - ANCX, IRWD And MPLX Traded By Insiders

Stocks with insider trader activity include ANCX, IRWD and MPLX

Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan

Astellas And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan

Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc.

Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase II clinical trial of linaclotide conducted in adults with opioid-induced constipation (OIC) met its primary endpoint.

First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of January 2016 Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options begin trading this week, for the January 2016 expiration.

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its third quarter 2015 and recent business activities.

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of a Phase Ib clinical study of IW-1973 and a Phase Ia clinical study of IW-1701, both of which are investigational soluble guanylate cyclase...

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today the initiation of a Phase IIb clinical trial evaluating two orally-administered colonic release formulations of...

'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon

'Mad Money' Lightning Round: I'm Not Tempted by Vonage, I Want Verizon

Cramer says keep Sierra Wireless, avoid Rackspace Hosting and take Weight Watchers gain and go.

Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities

Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities

One company's awful earnings can drag others down in the sector, making bargains for the taking, Cramer syas.

First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week of December 18th Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the December 18th expiration.

Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting

Ironwood Highlights Refractory GERD And Constipation Research At The American College Of Gastroenterology 2015 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced a series of oral and poster presentations at the American College of Gastroenterology 2015 Scientific Meeting in Honolulu, HI, October 16 to 21, 2015.

Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Third Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2015 investor update conference call and webcast at 4:30 p.

Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation

Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of its 72 mcg dose of linaclotide in adults with chronic idiopathic constipation (CIC) met the primary endpoint.

Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume

Ironwood Pharmaceuticals (IRWD) Flagged As Strong On High Volume

Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a strong on high relative volume candidate

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals To Present At Morgan Stanley Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 12:55 p.

First Week of IRWD October 16th Options Trading

First Week of IRWD October 16th Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the October 16th expiration.

Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its second quarter 2015 and recent business activities.

Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.

Ironwood And Allergan Enter Agreement To Co-Promote VIBERZI For Irritable Bowel Syndrome With Diarrhea (IBS-D) In The U.S.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today an agreement with Allergan plc for the U.

Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973

Ironwood Progresses SGC Stimulator Platform With Positive Top-Line Phase I Data On IW-1973

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator.

Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2015 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2015 investor update conference call and webcast at 4:30 p.

TheStreet Quant Rating: D- (Sell)